mpm is an early-stage life sciences venture investing firm with a track record of identifying and building world-class companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. mpm’s portfolio of companies aims to revolutionize the face of medicine across multiple areas including cancer, neuroscience, metabolic disorders, and regenerative medicine. with its deep experience, dedicated team of operating executives, and distinguished medical and scientific advisory board, mpm is powering novel medical breakthroughs that transform patient lives.
Company profile
Ticker
ONCR
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
473779757
ONCR stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
7 Aug 23
15-12G
Securities registration termination
3 Aug 23
DEFA14A
Additional proxy soliciting materials
3 Aug 23
8-K
Departure of Directors or Certain Officers
3 Aug 23
DEFA14A
Additional proxy soliciting materials
28 Jul 23
8-K
Departure of Directors or Certain Officers
28 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jul 23
Latest ownership filings
3
Brian J. Shea
16 Jun 23
3
Alexander Nolte
22 May 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
CHI Advisors LLC
13 Feb 23
SC 13G/A
Arkin Moshe
2 Feb 23
SC 13D/A
Flynn James E
19 Jan 23
SC 13D/A
Flynn James E
17 Jan 23
SC 13D/A
Flynn James E
3 Jan 23
4
James E Flynn
30 Dec 22
4
James E Flynn
27 Dec 22
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm |
Cash burn (monthly) | 1.50 mm | 4.52 mm | 9.90 mm | 7.37 mm | 5.82 mm | 4.64 mm |
Cash used (since last report) | 18.94 mm | 57.22 mm | 125.21 mm | 93.18 mm | 73.55 mm | 58.70 mm |
Cash remaining | 5.72 mm | -32.56 mm | -100.56 mm | -68.53 mm | -48.89 mm | -34.04 mm |
Runway (months of cash) | 3.8 | -7.2 | -10.2 | -9.3 | -8.4 | -7.3 |
Institutional ownership, Q2 2023
47.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 0 |
Closed positions | 27 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 253.96 mm |
Total shares | 12.32 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MPM Asset Management | 2.85 mm | $115.40 mm |
K2 HealthVentures Equity Trust | 2.59 mm | $4.54 mm |
MPM BioVentures 2014 | 2.40 mm | $37.31 mm |
MPM Oncology Impact Management | 2.38 mm | $96.27 mm |
Arkin Moshe | 1.07 mm | $0.00 |
Flynn James E | 1.02 mm | $426.00 k |
BCS Barclays | 9.50 k | $0.00 |
Your Advocates | 100.00 | $4.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Dec 22 | Flynn James E | Common Stock | Sell | Dispose S | Yes | No | 0.27 | 15,220 | 4.11 k | 284,697 |
30 Dec 22 | Flynn James E | Common Stock | Sell | Dispose S | Yes | No | 0.27 | 61,826 | 16.69 k | 1,156,308 |
30 Dec 22 | Flynn James E | Common Stock | Sell | Dispose S | Yes | No | 0.27 | 61,826 | 16.69 k | 1,156,309 |
29 Dec 22 | Flynn James E | Common Stock | Sell | Dispose S | Yes | No | 0.26 | 15,538 | 4.04 k | 299,917 |
29 Dec 22 | Flynn James E | Common Stock | Sell | Dispose S | Yes | No | 0.26 | 63,108 | 16.41 k | 1,218,134 |
29 Dec 22 | Flynn James E | Common Stock | Sell | Dispose S | Yes | No | 0.26 | 63,107 | 16.41 k | 1,218,135 |
28 Dec 22 | Flynn James E | Common Stock | Sell | Dispose S | Yes | No | 0.25 | 6,096 | 1.52 k | 315,455 |
28 Dec 22 | Flynn James E | Common Stock | Sell | Dispose S | Yes | No | 0.25 | 24,757 | 6.19 k | 1,281,242 |
28 Dec 22 | Flynn James E | Common Stock | Sell | Dispose S | Yes | No | 0.25 | 24,757 | 6.19 k | 1,281,242 |
27 Dec 22 | Flynn James E | Common Stock | Sell | Dispose S | Yes | No | 0.27 | 7,136 | 1.93 k | 321,551 |